Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 9/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 8/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5C | P41229 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289094 | 0.88 | ELANE (0.33) | LATS1LATS2HTTELANE | |
| SCHEMBL14289088 | 0.79 | GPR3 (0.43) | HTTELANE | |
| SCHEMBL22792959 | 0.77 | LATS1 (0.35) | LATS1LATS2KDM5CKDM5B | |
| SCHEMBL11202057 | 0.69 | KDM4C (0.43) | LATS1LATS2HTTCHUKKDM5A | |
| SCHEMBL22792562 | 0.67 | KDM4A (0.39) | LATS1LATS2HTTKDM5CKDM5B | |
| SCHEMBL22792740 | 0.67 | KDM4A (0.39) | LATS1LATS2HTTKDM5CKDM5B | |
| SCHEMBL14289090 | 0.65 | LATS1 (0.36) | LATS1LATS2KDM5CKDM5B | |
| SCHEMBL14289089 | 0.65 | LATS1 (0.38) | LATS1LATS2 | |
| SCHEMBL22792591 | 0.64 | — | — | |
| SCHEMBL30443054 | 0.62 | LATS1 (0.33) | LATS1LATS2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | LATS1 416/4885LATS2 559/4885HTT 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.